Hereditary Angioedema (HAE)
BioCryst is seeking to revolutionize treatment for Hereditary Angioedema (HAE) by developing orally-administered drugs to prevent and control HAE attacks
Our lead compound, BCX7353, is designed to be a once-daily capsule that prevents attacks by inhibiting plasma kallikrein.
BioCryst successfully completed APeX-1, a phase 2 clinical trial of BCX7353 in 75 HAE patients in 2017. BioCryst recently initiated APeX-2, a phase 3 clinical trial to test the efficacy and safety of BCX7353; and APeX-S, a trial to evaluate the long-term safety of the drug. These two trials put BioCryst on track to file for regulatory approval of BCX7353 in the second half of 2019.